Is ZYNE or EQR a better dividend investment in 2026?

ZYNE currently yields 153.85% with a 5% 5-year dividend growth rate. EQR yields 5.87% with 5% growth. The better choice depends on your goal: ZYNE offers higher current income.

What is the dividend yield difference between ZYNE and EQR?

ZYNE has a forward dividend yield of 153.85% ($2.00/share annually). EQR yields 5.87% ($3.47/share annually). The yield gap is 147.98 percentage points.

Home › Compare › ZYNE vs EQR

ZYNE vs EQR: Dividend Comparison 2026

ZYNE yields 153.85% · EQR yields 5.87%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ZYNE wins by $28.38M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ZYNE

● Live price

153.85%

Share price

$1.30

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.43M

Annual income

$12,477,713.99

Full ZYNE calculator →

EQR

● Live price

5.87%

Share price

$59.15

Annual div

$3.47

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47.8K

Annual income

$5,475.61

Full EQR calculator →

Portfolio growth — ZYNE vs EQR

📍 ZYNE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ZYNE	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ZYNE + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ZYNE pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZYNE

Annual income on $10K today (after 15% tax)

$13,076.92/yr

After 10yr DRIP, annual income (after tax)

$10,606,056.89/yr

EQR

Annual income on $10K today (after 15% tax)

$499.01/yr

After 10yr DRIP, annual income (after tax)

$4,654.27/yr

At 15% tax rate, ZYNE beats the other by $10,601,402.62/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZYNE + EQR for your $10,000?

ZYNE: 50%EQR: 50%

100% EQR50/50100% ZYNE

Portfolio after 10yr

$14.24M

Annual income

$6,241,594.79/yr

Blended yield

43.83%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ZYNE

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

-8.9

Piotroski

2/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+18.9% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZYNE buys

EQR buys

No recent congressional trades found for ZYNE or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricZYNEEQR

Forward yield	153.85% ✓	5.87%
Annual dividend / share	$2.00	$3.47 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$28.43M	$47.8K ✓
Annual income after 10y	$12,477,713.99 ✓	$5,475.61
Total dividends collected	$26.36M ✓	$23.0K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Hold	Hold

Year-by-year: ZYNE vs EQR ($10,000, DRIP)

Year	ZYNE Portfolio	ZYNE Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$26,085	$15,384.62	$11,380	$679.82	+$14.7K → ZYNE
2	$65,415	$37,504.84	$13,014	$837.25	+$52.4K → ZYNE
3	$157,896	$87,902.04	$14,961	$1,036.20	+$142.9K → ZYNE
4	$367,242	$198,293.18	$17,297	$1,289.22	+$349.9K → ZYNE
5	$823,976	$431,026.91	$20,121	$1,613.15	+$803.9K → ZYNE
6	$1,785,476	$903,821.11	$23,561	$2,030.84	+$1.76M → ZYNE
7	$3,740,825	$1,830,365.98	$27,783	$2,573.54	+$3.71M → ZYNE
8	$7,586,679	$3,583,996.66	$33,013	$3,284.39	+$7.55M → ZYNE
9	$14,910,849	$6,793,102.33	$39,547	$4,223.51	+$14.87M → ZYNE
10	$28,432,323	$12,477,713.99	$47,791	$5,475.61	+$28.38M → ZYNE

ZYNE vs EQR: Complete Analysis 2026

ZYNE — Stock

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Full ZYNE Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this ZYNE vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZYNE vs SCHD ZYNE vs JEPI ZYNE vs O ZYNE vs KO ZYNE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.